IN8Bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
Domain
in8bio.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$20.1M
Founded
2015
Tech Stack (25 technologies)
Frequently Asked Questions
What technologies does IN8Bio use?+
IN8Bio uses 25 technologies including Contact Form 7, Cookiebot, Google Analytics.
What industry is IN8Bio in?+
IN8Bio operates in the Biotechnology industry.
Where is IN8Bio based?+
IN8Bio is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026